Increasing Cardiac Capillary Angiogenesis in Coronary Microvascular Disease

Current Evidence-Based Treatment Approach

The European Society of Cardiology recommends beta-blockers as first-line therapy in patients with abnormal coronary flow reserve or elevated index of microcirculatory resistance and negative acetylcholine testing, as they increase diastolic perfusion time and reduce myocardial oxygen demand 1, 2
The European Society of Cardiology indicates ACE inhibitors in patients with documented microvascular dysfunction, particularly those with hypertension, diabetes, or heart failure, as they improve endothelial function 1, 2
The European Society of Cardiology suggests statins should be prescribed to all patients with coronary microvascular disease regardless of lipid levels, as they improve endothelial function and reduce inflammation 1, 2, 3
Lifestyle modifications including weight loss are essential components of therapy, as cardiovascular risk factors significantly impair microvascular function 1, 2

Ranolazine may reduce mechanical compression of the coronary microcirculation and improve coronary self-regulation, though evidence shows benefit primarily in patients with impaired coronary flow reserve 4
Ivabradine has demonstrated superiority over bisoprolol in improving coronary collateral flow and coronary flow reserve in microvascular angina patients, despite similar heart rate reduction 4
Calcium channel blockers can be used to slow heart rate and increase diastolic perfusion time 4, 1

Tailored treatment based on invasive coronary testing significantly reduces anginal symptoms compared to conventional non-guided therapy 1, 2, 8
Measurement of CFR and IMR during coronary angiography in patients with angina and non-obstructive coronary disease is recommended 1, 2, 8

Avoid vasodilators in patients with hyperthyroidism-related angina due to risk of reflex tachycardia 4
Beta-blockers are contraindicated in vasospastic angina as they can precipitate spasm by leaving α-mediated vasoconstriction unopposed 4
Nitrate tolerance develops with continuous administration, requiring intermittent dosing schedules 4
20-30% of patients remain symptomatic despite traditional antianginal therapy, necessitating consideration of alternative agents or pain modulators like tricyclic antidepressants 4